智通财经APP获悉，高盛发布研报称，金斯瑞生物科技(01548)2025财年上半年业绩表现好坏参半，毛利率持续受压，但除传奇生物外业务销售大致符预期，管理层将生命科学业务2025年指引从10%至15%轻微上调至13%至15%，预期该业务将维持稳健增长。高盛续予金斯瑞“买入”评级，目标价由27.34港元下调至26.25港元，将2025至2027年每股盈利预测从0.07、0.05及0.1美元，下调至亏损0.03、亏损0.01及盈利0.03美元，以反映盈利受压。
智通财经APP获悉，高盛发布研报称，金斯瑞生物科技(01548)2025财年上半年业绩表现好坏参半，毛利率持续受压，但除传奇生物外业务销售大致符预期，管理层将生命科学业务2025年指引从10%至15%轻微上调至13%至15%，预期该业务将维持稳健增长。高盛续予金斯瑞“买入”评级，目标价由27.34港元下调至26.25港元，将2025至2027年每股盈利预测从0.07、0.05及0.1美元，下调至亏损0.03、亏损0.01及盈利0.03美元，以反映盈利受压。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.